Latest News
by Chip Hennen Redwood City, CA (March 11, 2011) – EndoGastric Solutions, the leader in the emerging field of Natural Orifice Surgery (NOS), announced today that is has received the distinction of being named one of the Wall Street Journal’s “The Next Big Thing” Top 50 venture capital-funded companies in America. EndoGastric Solutions was the third highest ranking medical device company and one of only eight health care companies recognized in the list. The list, published yesterday, identifies organizations demonstrating the “greatest promise to succeed.” To be eligible, companies must have received an equity round of financing in the past three years and be valued at less than $1 Billion. Over 5,000 eligible companies were ranked on five criteria:
“We are honored to be named as one of America’s most promising venture-backed companies by the Wall Street Journal,” commented Thierry Thaure, President and Chief Executive Officer of EndoGastric Solutions. “Our future success will be a result of our ability to develop innovative technologies, teach safe and effective procedures, and partner with surgeons and hospitals in building patient awareness. We are proud to receive this distinction, but the real honor is the ability to improve the lives of tens of millions of patients around the world.” Click here to see the Wall Street Journal's "Next Big Thing" list of the top 50 venture capital-funded companies.
About EndoGastric Solutions® For more information about EndoGastric Solutions and its products, EsophyX® and StomaphyX®, please visit: http://www.endogastricsolutions.com View the GERDHelp.com website, providing patient information on the symptoms and causes of GERD, as well as the treatment options available for it, including the incisionless TIF procedure. PRESS CONTACT: CUSTOMER CONTACT: EUROPEAN CUSTOMER CONTACT: NP02252-01A ### |
NP01366-01B